Wuhan YZY Biopharma Co (HKSE:02496) Equity-to-Asset : 0.42 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Wuhan YZY Biopharma Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$139.63 Mil. Wuhan YZY Biopharma Co's Total Assets for the quarter that ended in Dec. 2023 was HK$329.91 Mil.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Equity-to-Asset or its related term are showing as below:

HKSE:02496' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.52 Max: 0.72
Current: 0.42

During the past 3 years, the highest Equity to Asset Ratio of Wuhan YZY Biopharma Co was 0.72. The lowest was 0.42. And the median was 0.52.

HKSE:02496's Equity-to-Asset is ranked worse than
69.92% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02496: 0.42

Wuhan YZY Biopharma Co Equity-to-Asset Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Equity-to-Asset Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

0.72

0.52

0.42

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Dec23
Equity-to-Asset	0.72	0.52	0.42

Competitive Comparison of Wuhan YZY Biopharma Co's Equity-to-Asset

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Equity-to-Asset falls into.

Wuhan YZY Biopharma Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Wuhan YZY Biopharma Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	139.625	/	329.91
	=

Wuhan YZY Biopharma Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	139.625	/	329.91
	=

Wuhan YZY Biopharma Co (HKSE:02496) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Wuhan YZY Biopharma Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com/

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.

Executives

Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie	2201 Interest of corporation controlled by you
Wu Shangzhi	2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines